

REMARKS

In accordance with 37 CFR § 1.125(b), a substitute specification is submitted herewith. The substitute specification is provided to correct inadvertent typographical and grammatical errors and to insert section headings. The substitute specification includes no new matter. A marked up version of the substitute specification showing the changes to the specification of record is submitted herewith.


Claims 6, 13 and 22 have been amended to correct inadvertent typographical errors. No new matter has been added by these amendments. A marked up version of the claims showing the amendments of the claims is submitted herewith.

Favorable consideration and allowance of all pending claims is earnestly solicited.

Respectfully submitted,

DORSEY & WHITNEY LLP

Date: April 11, 2002

  
Janet M. MacLeod  
Reg. No. 35,263  
250 Park Avenue  
New York, NY 10177  
(212) 415-9200

**MARKED-UP VERSION SHOWING CHANGES**

IN THE SPECIFICATION

New specification attached.

IN THE CLAIMS

--6. (Amended) The method according to claim 5 wherein a nucleotide-degrading enzyme is included [durinig] during the primer extension reaction.--

--13. (Amended) The method according to claim 11 wherein said polymorphism is not present in a homopolymeric sequence and will not be preferentially amplified in any PCR-type reactions.--

--22. (Amended) The method according to claim 21 wherein a nucleotide-degrading enzyme is included [durinig] during the primer extension reaction.--